



**UNITED STATES
NUCLEAR REGULATORY COMMISSION**

REGION III
2056 WESTINGS AVENUE, SUITE 400
NAPERVILLE, IL 60563-2657

May 23, 2025

Laura T. Speer-Smith, M.S., Radiation Safety Officer
Metro Detroit Cardiovascular Associates
11900 E 12 Mile Rd., Ste. 103
Warren, MI, 48093

**SUBJECT: LINGAREDDY DEVIREDDY, M.D., P.C. REQUEST FOR WRITTEN CONSENT
TO DIRECT LICENSE TRANSFER**

Enclosed is Amendment No. 7 to your U.S. Nuclear Regulatory Commission (NRC) Materials License No. 21-32388-01 in accordance with your request.

By application dated October 15, 2024 (Agencywide Documents Access and Management System (ADAMS) Accession Number ML24331A056), Lingareddy Devireddy, M.D., P.C. submitted to the U.S. Nuclear Regulatory Commission (NRC) a request for written consent to a direct transfer of control of NRC Materials License number 21-32388-01. In accordance with Section 184 of the Atomic Energy Act of 1954, as amended (AEA), and 10 CFR 30.34, the NRC consents to the transfer.

Lingareddy Devireddy, M.D., P.C. is authorized by the NRC for the possession and use of byproduct material under Part 30. By letter dated October 15, 2024, Lingareddy Devireddy, M.D., P.C. requested written consent to the direct transfer of control of its license from the NRC. Because the license was issued under 10 CFR Part 30, "Rules of General Applicability to Domestic Licensing of Byproduct Material," the NRC must find that the transfer is in accordance with the provisions of the AEA and, if so, must give its consent in writing prior to the transfer, in accordance with Section 184 of the AEA and 10 CFR 30.34(b). Additionally, the NRC staff reviewed the direct transfer of control request using the guidance in NUREG-1556, Volume 15, Revision 1, "Consolidated Guidance About Materials Licenses – Guidance About Changes of Control and About Bankruptcy Involving Byproduct, Source, or Special Nuclear Materials Licenses," dated June 2016.

10 CFR 30.34(b) states:

- (1) No license issued or granted pursuant to the regulations in parts 30 through 36, and 39 nor any right under a license shall be transferred, assigned or in any manner disposed of, either voluntarily or involuntarily, directly or indirectly, through transfer of control of any license to any person, unless the Commission shall, after securing full information, find that the transfer is in accordance with the provisions of the Act and shall give its consent in writing.
- (2) An application for transfer of license must include:

- (i) The identity, technical and financial qualifications of the proposed transferee; and
- (ii) Financial assurance for decommissioning information required by [10 CFR] 30.35.

As described in ADAMS package accession number ML24331A056, the direct transfer of control will result as Lingareddy Devireddy, MD, PC has entered into a definitive agreement with Metro Detroit Cardiovascular Associates to maintain the facilities and NRC Lic. No. 21-32388-01. Following the December 1, 2024, proposed transaction closing, Metro Detroit Cardiovascular Associates site will continue to operate in the ordinary course of business. The NRC staff finds that the licensee request adequately provides a complete and clear description of the proposed transaction, consistent with 10 CFR 30.34(b) and Chapter 5 and Appendix E of NUREG-1556, Vol. 15, Rev. 1. The sufficiency of the description is evaluated below.

The request for a direct transfer of ownership was posted for public comment on the NRC website for 30 days in accordance with 10 CFR Part 2, Subpart M and as described in NRC's Regulatory Issue Summary 2014-08, Revision 1. No comments were received from members of the public.

In the request for a direct transfer of ownership, Lingareddy Devireddy, M.D., P.C. provided information regarding its current decommissioning funding plans. Based on the information provided, Lingareddy Devireddy, M.D., P.C. is not required to have financial assurance for decommissioning because of the types and amount of material authorized in its license. The NRC staff finds that the licensee's request adequately provided information for financial assurance for decommissioning, consistent with 10 CFR 30.34(b) and Chapter 5 and Appendix E of NUREG-1556, Vol. 15, Rev. 1.

Further, the NRC conducted an inspection of Lingareddy Devireddy, M.D., P.C. on 11/29/2023 at 11900 E. Twelve Mile Rd., Warren, MI 48093. The NRC identified no violations.

Additionally, as described in its request, Metro Detroit Cardiovascular Associates commits that it:

- A. There are no changes in personnel named in the license,
- B. All locations will remain open and in business and maintain each individual license.
- C. All records concerning the safe and effective decommissioning of the facility will be transferred to Metro Detroit Cardiovascular Associates pursuant to 10 CFR 30.55(g); understands that they will be responsible for transferring records to the appropriate NRC Region III offices prior to future termination of the NRC license. All NRC records from the site will remain onsite. Area and wipe test surveys will continue to be performed as required.
- D. There are no planned changes in organization, location, facilities, equipment, procedures, radiation safety programs use, possession, waste management, or personnel
- E. There are no changes in use, possession, or storage of licensed materials,
- F. All surveillance items and records, including radioactive material inventory and accountability requirements, are current and will be current at the time of transfer. All surveillance requirements and records are current, within the requirements of 10 CFR 35

and 37, and up to date as required. All calibrations, leak test records, and surveys are current and performed as always on schedule per U.S. NRC regulations.

- G. There is no contamination at any of the facilities listed on the license
- H. Both Lingareddy Devireddy, MD, PC, and Metro Detroit Cardiovascular Associates agree to the change in ownership.
- I. Metro Detroit Cardiovascular Associates will abide by all constraints, conditions, requirements, representations, and commitments identified in the existing license agreements

Based on these commitments, the NRC staff finds that the licensee request adequately documents the constraints, license conditions, requirements, representations, and commitments made by the transferee, consistent with 10 CFR 30.34(b) and Chapter 5 and Appendix E of NUREG-1556, Vol. 15, Rev. 1.

The primary owner of Metro Detroit Cardiovascular Associates, Dr. Narsumha Gottam, holds NRC license number 21-32506-01, authorizing the possession of byproduct material for diagnostic procedures. The NRC staff used the guidance provided by the NRC's Office of Nuclear Material Safety and Safeguards' "Checklist to provide a basis for confidence that radioactive materials will be used as specified on the application," January 29, 2019 revision. The purpose of this checklist is for the NRC to obtain reasonable assurance from new license applicants or NRC licensees transferring control of licensed activities that the licensed material will be used for its intended purpose and not for malevolent use. Therefore, for security purposes, Metro Detroit Cardiovascular Associates is considered a known entity.


An environmental assessment for this action is not required because this action is categorically excluded under 10 CFR 51.22(c)(21).

The staff has reviewed the request for a direct transfer of control of 21-32388-01. The NRC staff finds that the direct transfer of control is in accordance with Section 184 of the AEA and 10 CFR 30.34(b) and consents to the transfer. Please note that you will need to notify us promptly, in writing, after the transaction has been finalized and include a signed copy of the sales agreement confirming completion of the transaction. If this planned sale has not been consummated within 30 days of the date of this letter, please notify us in writing.

Future changes in the licensee's name, licensed use, licensed materials, licensed location, persons responsible for licensed material, or other changes to the corporate organizational structure require submission of a request to amend the license or a request to transfer the license. NRC approval must be received prior to implementation of any such proposed change.

In accordance with 10 CFR 2.390, a copy of this letter will be available electronically for public inspection in the NRC Public Document Room or from the Publicly Available Records component of NRC's Agencywide Documents Access and Management System (ADAMS). ADAMS is accessible from the NRC website at <https://www.nrc.gov/reading-rm/adams.html>. If you have any questions regarding this letter, please contact Erin Kennedy at 505-699-3675 or via electronic mail at erin.kennedy@nrc.gov.

Sincerely,

A handwritten signature in blue ink that reads "Erin Kennedy". The signature is written in a cursive style with a large, stylized "E" and "K".

Erin Kennedy
Health Physicist
Materials Licensing Branch

Docket No.: 030-35982
License No.: 21-32388-01
Control No.: 644262

Enclosure: Amendment No. 7 to NRC License No. 21-32388-01